Milenko Cicmil
InvestorPartner at Cure Ventures
Boston, Massachusetts
Writes $100K – $5M checks · typically $1.5M
About
Associated with portfolio company Tasca Therapeutics, which works on post-translational modification to expand the druggable proteome.
Experience
- University of ReadingVisiting Research Fellow at Univ. of Reading, UKcurrent2020 — presentUnited Kingdom
- Cure VenturesPartnercurrent2021 — presentUnited States
- AMP DiscoveryChairman Of The Board AMP Discovery2021 — 2022
- IpsenVice President Global Head of external Innovation2019 — 2021Cambridge, Massachusetts, USA
- FogPharmaVice President - Translational Biology2017 — 2019Cambridge, USA
- MerckDirector at Merck Innovation Hub2016 — 2017Cambridge USA
- MerckDirector Pharmacology Immuno-Oncology and Immunomodulation2013 — 2016Greater Boston Area
- MerckDirector In vivo Pharmacology R&I2011 — 2013Boston, US
- AstraZenecaGroup Leader Integrative Pharmacology Discovery Bioscience - Inflammation2007 — 2011Leicester, United Kingdom
- AstraZenecaSenior Research Scientist2004 — 2007Leicester, United Kingdom
- GE HealthcareSenior Research Scientist2002 — 2004Amersham UK
- Cancer Research UKTranslational Science - Research Fellow2000 — 2002London, United Kingdom
Education
- King's College LondonBachelor’s Degree, Cell/Cellular and Molecular Biology1994 — 1997
- University of ReadingDoctor of Philosophy (Ph.D.), Molecular Pharmacology1997 — 2000
Skills & more
Biochemistry5Biomarker Discovery7Biomarkers7Biotechnology5CRO3Cell Culture3Clinical Development6DMPK2Drug Design4Drug Development14Drug Discovery25In Vitro7
+6 more
In VivoLead ChangeLifesciencesPharmaceutical IndustryPharmacologyTarget IdentificationFrom Milenko's professional profile.
Same school
Also attended King's College London169
Harry StebbingsFounder & General Partner at 20VCDominic JacquessonInvestor at Index VenturesJohn HortonInvestor at DN CapitalBob ThomasPartner at OxxKatherineHealthcare Investment Lead at Hummingbird VenturesÖzge Gizem YerlikayaGeneral Counsel at Idacapital
+ 163 more
Also attended University of Reading42
Ziad Al-TunisiBoard of Directors (Chairman) at Nuwa CapitalTony CorbinGeneral Partner & Chief Financial Officer at White Star CapitalRobert Whitby-SmithInvestor at AlbionVCPierce PolakSenior Associate at Fuel VenturesCollin McCollAnalyst at First Bight VenturesToby LovettGeneral Counsel at World Fund
+ 36 more
Shared employers
Also worked at Ipsen9
Awny FarajallahChief Medical Officer at Takeda VenturesPierce PolakSenior Associate at Fuel VenturesClement SalqueAssociate at Bioqube VenturesRachel SchillingConsulting at Rock HealthPradyumna MurharInvestor at Alkemi Growth CapitalFabienne BerthetInvestor at Angels Santé
+ 3 more
Also worked at FogPharma6
Also worked at Merck90
Anika GuptaInvestor at GV (Google Ventures)Sam BlackmanEntrepreneur in Residence at GV (Google Ventures)Catherine Pearce, DHSc, MBAAdvisor at CincyTechDavid MollerInvestor at Third Rock VenturesAndrea van ElsasInvestor at Third Rock VenturesDavid KaufmanInvestor at Third Rock Ventures
+ 84 more
Also worked at AstraZeneca52
Jung Lee, PhDVenture Partner at Adelphi Ventures Management, LlcJohan LundVenture Partner at ScietyAnnie VemuSenior Associate at Longwood FundIliam BarkinoInvestor at IndustrifondenSara JawadInvestor at IndustrifondenDamian Crowtherex-AstraZeneca at PICUS CAPITAL
+ 46 more
Colleagues at Cure Ventures
Albert J. Robichaud
Partner at Cure Ventures
Annie Mitsak
Partner at Cure Ventures
Bill Amsbaugh
CTO and Partner at Cure Ventures
Courtney Turner
Director of Finance at Cure Ventures
David Fallace
Managing Partner at Cure Ventures
Dr. Michael Aberman
Investor at Cure Ventures
Dr. Milenko Cicmil
Investor at Cure Ventures
Drew King
CFO and Partner at Cure Ventures




.avif)


































